Gross Profit Margin (Quarterly) Chart

Historical Gross Profit Margin (Quarterly) Data

View and export this data back to 2000. Start Trial.
Date Value
June 30, 2026 42.89%
March 31, 2026 34.70%
December 31, 2025 35.67%
September 30, 2025 34.61%
June 30, 2025 27.44%
March 31, 2025 38.59%
December 31, 2024 16.88%
September 30, 2024 36.95%
June 30, 2024 35.67%
March 31, 2024 23.13%
December 31, 2023 -50.11%
September 30, 2023 33.14%
June 30, 2023 -75.56%
March 31, 2023 -14.43%
December 31, 2022 12.01%
September 30, 2022 -9.32%
June 30, 2022 36.03%
March 31, 2022 46.31%
December 31, 2021 46.76%
September 30, 2021 45.68%
June 30, 2021 46.08%
March 31, 2021 50.14%
December 31, 2020 60.85%
September 30, 2020 45.94%
June 30, 2020 33.45%
Date Value
March 31, 2020 40.29%
December 31, 2019 14.42%
September 30, 2019 41.35%
June 30, 2019 23.44%
March 31, 2019 35.03%
December 31, 2018 32.81%
September 30, 2018 22.16%
June 30, 2018 16.25%
March 31, 2018 47.83%
December 31, 2017 -158.4%
September 30, 2017 41.61%
June 30, 2017 24.61%
March 31, 2017 23.68%
December 31, 2016 -83.88%
September 30, 2016 17.12%
June 30, 2016 45.61%
March 31, 2016 42.67%
December 31, 2015 -76.48%
September 30, 2015 19.76%
June 30, 2015 18.48%
March 31, 2015 28.00%
December 31, 2014 -64.84%
September 30, 2014 23.67%
June 30, 2014 28.82%
March 31, 2014 34.77%

Gross Profit Margin Definition

Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.

Read full definition.

Gross Profit Margin (Quarterly) Range, Past 5 Years

View Gross Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Gross Profit Margin (Quarterly) Benchmarks

View Gross Profit Margin (Quarterly) Benchmarks
Start Trial
West Pharmaceutical Services, Inc. 37.83%
Agilent Technologies, Inc. 55.48%
Anika Therapeutics, Inc. 65.15%
Bio-Rad Laboratories, Inc. 53.12%
Bruker Corp. 49.65%

Gross Profit Margin (Quarterly) Related Metrics